.Pharmacolibrary.Drugs.ATC.G.G01AA03 .Pharmacolibrary.Drugs.ATC.G.G01AA03| name: | AmphotericinB |
| ATC code: | G01AA03 | route: | intravenous |
| n-compartments | 2 |
Amphotericin B is a polyene antifungal agent used primarily in the treatment of severe, systemic fungal infections. It is considered a drug of choice for life-threatening mycoses, including cryptococcal meningitis and invasive candidiasis. Despite its effectiveness, it is associated with significant nephrotoxicity and infusion-related reactions. Conventional amphotericin B deoxycholate is still in use, while lipid formulations are also approved to reduce toxicity.
Pharmacokinetic parameters in adult patients with systemic fungal infections, administered intravenous amphotericin B deoxycholate (non-lipid formulation).
Groll, AH, et al., & Brüggemann, RJM (2019). Clinical Pharmacokinetics, Pharmacodynamics, Safety and Efficacy of Liposomal Amphotericin B. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 68(Suppl 4) S260–S274. DOI:10.1093/cid/ciz076 PUBMED:https://pubmed.ncbi.nlm.nih.gov/31222253
Würthwein, G, et al., & Walsh, TJ (2005). Population pharmacokinetics of amphotericin B lipid complex in neonates. Antimicrobial agents and chemotherapy 49(12) 5092–5098. DOI:10.1128/AAC.49.12.5092-5098.2005 PUBMED:https://pubmed.ncbi.nlm.nih.gov/16304177
Nath, CE, et al., & Earl, JW (2001). Population pharmacokinetics of amphotericin B in children with malignant diseases. British journal of clinical pharmacology 52(6) 671–680. DOI:10.1046/j.0306-5251.2001.01496.x PUBMED:https://pubmed.ncbi.nlm.nih.gov/11736878